(Q33394104)

26 July 2017

1 reference

title

A review of the treatment of chronic hepatitis C virus infection in cirrhosis (English)

1 reference

26 July 2017

0 references

1 reference

1 reference

1 reference

1 reference

Alessio Aghemo

2

0 references

author name string

Elena Vezali

series ordinal

1

1 reference

26 July 2017

Massimo Colombo

series ordinal

3

1 reference

26 July 2017

publication date

1 December 2010

1 reference

26 July 2017

published in

Clinical Therapeutics

1 reference

26 July 2017

volume

32

1 reference

26 July 2017

issue

13

1 reference

26 July 2017

page(s)

2117-2138

1 reference

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Natural history of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Treating hepatitis C in patients with cirrhosis: the effort is worth it.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Ribavirin improves early responses to peginterferon through improved interferon signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Natural history and clinical impact of cryoglobulins in chronic hepatitis C: 10-year prospective study of 343 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Diagnosis, management, and treatment of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Treatment of chronic hepatitis C virus infection with pegylated interferon and ribavirin in cirrhotic patients awaiting liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Long-term results of liver transplantation in older patients 60 years of age and older

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Liver Transplant Recipients Older Than 60 Years Have Lower Survival and Higher Incidence of Malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

The association between hepatitis C infection and survival after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Treating hepatitis C infection in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Rejection under alpha interferon therapy in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Long-term antiviral therapy for recurrent hepatitis C after liver transplantation in nonresponders: biochemical, virological, and histological impact

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

Hepatitis C therapy before and after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900022-1

7 January 2021

10.1016/S0149-2918(11)00022-1

Identifiers

DOI

1 reference

26 July 2017

1 reference